Ischemic Stroke Clinical Trial
Official title:
The Language Functional Reorganization Following Subcortical Cerebral Infarction: A Longitudinal fMRI Study
Post stroke aphasia (PSA) is one of the most frequently happened deficiency of stoke,
affecting speaking,comprehension, writing and reading of language. Generally, PSA is commonly
seen in cortical damage, but in recent years it has been found that subcortical injury is
also an important cause of PSA, which is called subcortical aphasia. Using fMRI technology,
the investigators aim to investigate the language function of patients with subcortical
cerebral infarction at different stages of recovery , and explored the mechanism of
post-injury language reorganization in the brain.
The investigators recruited 60 first-episode acute cerebral infarction patients with one-side
lesion in subcortical white matter (40 with left injury and 20with right injury) and 20
health volunteers. All participants are right-handed, and screened with MMSE, HAMD and HAMA
to exclude cases of psychosis, post-stroke dementia and depression. Each participant was
arranged to have three test sessions at different stages after the infarction (T1:within 3
days after onset of the stroke ; T2:28 ±3days after onset; T3: 90±3days after onset), with
fMRI and Western aphasia battery (WAB) in each session.
The purpose of this study is to explore the pathogenesis of subcortical aphasia, and to
understand the dynamic reorganization of language network during the recovery of language
function.
The participants were recruited from inpatients with acute ischemic stroke in Department of
Cerebrovascular disease, The Guangzhou General Hospital of Guangzhou Military Command. The
diagnose of ischemic stroke was made using the diagnostic criteria of the International
Association of Neurological Diseases and Stroke Association in 1982. The classification
criterias for ischemic stroke were based on the current international TOAST etiological
classification method.
The study passed the approval of the ethics committee of General Hospital of Guangzhou
Military Command , and all participants or their guardian signed informed consent. According
to the location and diagnostic criteria, the participants were divided into three groups:
left hemisphere infarction patients group ,right hemisphere infarction patients group and
normal healthy control group. The participants performed 3 language functional behavior tests
and functional magnetic resonance (fMRI) tests within3 days,28 ±3days ,90±3days after the
onset of cerebral infarction. In the healthy control group, the above examination was
performed only 1 times. Language functional behavioral assessments included the Chinese
version of Western Aphasia Battery(WAB), spontaneous language frequency test(SLFT) and
picture naming test(PNT). Examines of fMRI included task-state fMRI , resting-state fMRI and
diffusion tensor imaging(DTI).
Task state function magnetic resonance design:Using the block design, each sequence uses the
"baseline-stimulus-baseline-stimulus-baseline
-stimulus-baseline-stimulus-baseline-stimulus-baseline-stimulus-baseline-stimulus-baseline"
model. The first baseline duration is 24s. The following baseline duration and duration of
stimulus are 18s, each sequence is 240s, a total of three sequences. Scan 12min. From the
Snodgrass picture database, 54 animal pictures and 54 tool pictures can be accurately
identified by all subjects. Repeat 6 animal chunk and 6 tool naming chunks, six pictures of
each block for 18 seconds. Choose the abstract map of all the American skunk as the baseline
map of the animal name, and select the simple arrow picture as the baseline map of the tool.
In order to avoid repetition effect after practice, the pictures used in the design of MRI
are not repeated in speech behavior assessment. At baseline, subjects were asked to identify
the direction of the arrow image and the tail direction of the skunk by silently speaking
"upright" or "inverted". The subjects received task familiarization training before testing
to ensure that there was no meaningless picture naming in baseline tasks, but location
judgment. The design of language task is based on the design of Damasio. In the task state of
magnetic resonance scanning, the patient is required to read and name the silent images of
the visual images. The visual information is written by the DMDX software, the picture is
projected through the brain functional audio-visual stimulation system (SA-9900) to the
screen, and the subjects are placed on the head line. The reflector on the circle is
observed.
Resting-state fMRI:During the rest-state fMRI scan, no task instruction was given to the
participates, and the participates were completely relaxing, closing their eyes, breathing
calmly, keeping their head still, but could not fall asleep, tried to avoid any systematic
thinking activities, scanning 8min.
Functional magnetic resonance data acquisition:Cranial scanning was performed using the
HDX3.0Tesla superconducting magnetic resonance scanner of the US GE company. The 8 channel
phased array head coil is the receiving coil, and the scanning sequence and parameters are as
follows:
1. T1 structure imaging using FSPGR BRAVO sequence. The parameters included: time of
repetition, 8.86 ms; time of echo, 3.52 ms; field of view, 24×24 cm2; in-plane
resolution,256×256; slice thickness, 1 mm;interslice gap, 1 mm; and number of slices,
176.
2. Echo-Planar Imaging (EPI) was used to acquire task-state fMRI data.The parameters
included: time of repetition, 3000ms; time of echo, 40 ms; field of view, 24×24 cm2;
in-plane resolution,64×64; slice thickness, 4 mm; interslice gap, 1 mm; and number of
slices, 34. Scan a sequence of 240s, a total of 12 min.
3. Echo-Planar Imaging (EPI) was used to acquire rest-state fMRI data.The parameters
included: time of repetition, 3000ms; time of echo, 40 ms; field of view, 24×24 cm2;
in-plane resolution,64×64; slice thickness, 4 mm; interslice gap, 1 mm; and number of
slices, 34. A total of 8 min.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A |